Allan Reine - 21 May 2025 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role: Chief Executive Officer, Director
Signature: /s/ Ryan Brown, attorney-in-fact
Issuer symbol: PRME
Transactions as of: 21 May 2025
Transactions value $: $147,150
Form type: 4
Filing time: 22 May 2025, 16:18:34 UTC
Previous filing: 19 May 2025
Next filing: 05 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Reine Allan	Chief Executive Officer, Director	C/O PRIME MEDICINE, INC., 60 FIRST STREET, CAMBRIDGE	/s/ Ryan Brown, attorney-in-fact	22 May 2025	0001714023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRME	Common Stock	Purchase	$147K	+125K		$1.18	125K	21 May 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.20, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.20, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each separate price within the range set forth in this footnote.